DuPont's ( DD) fourth-quarter profit topped analysts' expectations as growth in overseas markets helped offset slower sales in the U.S. and higher commodity costs.

The Wilmington, Del., chemical giant's net income slipped to $545 million, or 60 cents a share, from $871 million, or 94 cents a share, a year earlier.

The decline reflected a one-time tax gain in the year-ago period. Excluding items in both periods, DuPont's earnings per share rose to 57 cents from 45 cents a year earlier.

Analysts, on average, were looking for earnings of 49 cents a share for the recent quarter, according to Thomson Financial.

DuPont's sales rose to $6.98 billion from $6.27 billion the prior year, topping Wall Street's expectation of $6.67 billion.

Outside the U.S., sales jumped 14%, boosted by 20% growth in emerging markets. Currency gains added 4% to sales. In the U.S., sales climbed 5% to $2.3 billion.

DuPont said that local selling-price gains more than offset rises in ingredient costs.

The company reiterated its forecast given earlier this month for 2008 earnings of $3.35 to $3.55 a share. For the first quarter, DuPont predicts a profit of $1.12 to $1.17 a share, bracketing analysts' average forecast of $1.15.

Shares of DuPont recently were up 15 cents, or 0.4%, to $42.85.

This article was written by a staff member of TheStreet.com.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says